Drug Combination Details
| General Information of the Combination (ID: C50414) | |||||
|---|---|---|---|---|---|
| Name | Paclitaxel NP Info | + | Amifostine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Uterine cancer
[ICD-11: 2C76]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | Hec50co | Endometrial cancer | Homo sapiens | |||
| In-vivo Model | Amifostine effect on in vivo tumor growth was tested in athymic mice. | |||||
| Experimental
Result(s) |
Amifostine and paclitaxel shown a potential anticancer synergistic effect in vitro and in vivo, whereas amifostine maintained a protective role in peripheral blood profiles. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. Cancer Res. 2005 Oct 15;65(20):9517-24. | |||
